UY31616A1 - Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica - Google Patents
Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéuticaInfo
- Publication number
- UY31616A1 UY31616A1 UY031616A UY31616A UY31616A1 UY 31616 A1 UY31616 A1 UY 31616A1 UY 031616 A UY031616 A UY 031616A UY 31616 A UY31616 A UY 31616A UY 31616 A1 UY31616 A1 UY 31616A1
- Authority
- UY
- Uruguay
- Prior art keywords
- tetrahydroquinoxaline
- preparation
- therapeutics
- application
- urea derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan compuestos derivados de urea de tetrahidroquinoxalina que responden a la fórmula (I), donde los sustituyentes e índices son tales como se definen en la memoria descriptiva y en las reivindicaciones. Se divulga también los procedimiento de preparación y su aplicación terapéutica en la modulación de la actividad de la 11B(Beta)-hidroxiesteroide deshidrogenada de tipo 1 (11B(Beta)HSD1), como el caso del síndrome metabólico o de la diabetes tipo 2 no dependiente de insulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0800429A FR2926817B1 (fr) | 2008-01-28 | 2008-01-28 | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
FR0804521A FR2934858B1 (fr) | 2008-08-08 | 2008-08-08 | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31616A1 true UY31616A1 (es) | 2009-08-31 |
Family
ID=41037885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY031616A UY31616A1 (es) | 2008-01-28 | 2009-01-28 | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica |
Country Status (24)
Country | Link |
---|---|
US (2) | US8211892B2 (es) |
EP (1) | EP2238126B1 (es) |
JP (1) | JP2011510919A (es) |
KR (1) | KR20100111308A (es) |
CN (1) | CN101981026A (es) |
AR (1) | AR070255A1 (es) |
AU (1) | AU2009224546B2 (es) |
BR (1) | BRPI0906567A2 (es) |
CA (1) | CA2713367A1 (es) |
CL (1) | CL2009000173A1 (es) |
CO (1) | CO6290672A2 (es) |
CR (1) | CR11596A (es) |
DO (1) | DOP2010000230A (es) |
EA (1) | EA201070895A1 (es) |
EC (1) | ECSP10010368A (es) |
IL (1) | IL207195A (es) |
MA (1) | MA32098B1 (es) |
MX (1) | MX2010008290A (es) |
NI (1) | NI201000130A (es) |
PA (1) | PA8813701A1 (es) |
PE (1) | PE20091323A1 (es) |
TW (1) | TW200936136A (es) |
UY (1) | UY31616A1 (es) |
WO (1) | WO2009112691A2 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
FR2948370B1 (fr) * | 2009-07-27 | 2013-04-05 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
FR2948369B1 (fr) * | 2009-07-27 | 2013-04-12 | Sanofi Aventis | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique |
US8933229B2 (en) | 2009-11-11 | 2015-01-13 | Sumitomo Dainippon Pharma Co., Ltd. | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative |
KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
WO2011078101A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | アダマンタンアミン誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US8901316B2 (en) | 2010-08-09 | 2014-12-02 | Shionogi & Co., Ltd. | Process for preparing aminoadamantyl carbamate derivatives |
TW201212908A (en) | 2010-09-03 | 2012-04-01 | Dainippon Sumitomo Pharma Co | Cyclic amide derivative |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
JP6043767B2 (ja) * | 2014-09-26 | 2016-12-14 | 株式会社アステム | 番組出力装置、補助情報管理サーバ、番組と補助情報の出力方法、及びプログラム |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
CN109956958B (zh) * | 2019-04-02 | 2020-06-16 | 河北合佳医药科技集团股份有限公司 | 一种7-氨基-3-甲氧基甲基-3-头孢烯-4-羧酸合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
GB0505541D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
PE20080344A1 (es) * | 2006-06-27 | 2008-06-09 | Sanofi Aventis | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 |
TW200811158A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
US8222417B2 (en) * | 2007-06-27 | 2012-07-17 | Taisho Pharmaceutical Co., Ltd | Compound having 11β-HSD1 inhibitory activity |
WO2009020140A1 (ja) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
-
2009
- 2009-01-23 TW TW098103125A patent/TW200936136A/zh unknown
- 2009-01-26 AR ARP090100229A patent/AR070255A1/es not_active Application Discontinuation
- 2009-01-26 PE PE2009000105A patent/PE20091323A1/es not_active Application Discontinuation
- 2009-01-27 EA EA201070895A patent/EA201070895A1/ru unknown
- 2009-01-27 CN CN2009801113945A patent/CN101981026A/zh active Pending
- 2009-01-27 JP JP2010543545A patent/JP2011510919A/ja active Pending
- 2009-01-27 BR BRPI0906567-9A patent/BRPI0906567A2/pt not_active IP Right Cessation
- 2009-01-27 EP EP09720707.0A patent/EP2238126B1/fr active Active
- 2009-01-27 AU AU2009224546A patent/AU2009224546B2/en not_active Ceased
- 2009-01-27 PA PA20098813701A patent/PA8813701A1/es unknown
- 2009-01-27 MX MX2010008290A patent/MX2010008290A/es active IP Right Grant
- 2009-01-27 WO PCT/FR2009/000083 patent/WO2009112691A2/fr active Application Filing
- 2009-01-27 KR KR1020107019130A patent/KR20100111308A/ko active Search and Examination
- 2009-01-27 CA CA2713367A patent/CA2713367A1/fr not_active Abandoned
- 2009-01-28 UY UY031616A patent/UY31616A1/es not_active Application Discontinuation
- 2009-01-28 CL CL2009000173A patent/CL2009000173A1/es unknown
-
2010
- 2010-07-23 EC EC2010010368A patent/ECSP10010368A/es unknown
- 2010-07-25 IL IL207195A patent/IL207195A/en not_active IP Right Cessation
- 2010-07-26 US US12/843,124 patent/US8211892B2/en not_active Expired - Fee Related
- 2010-07-26 NI NI201000130A patent/NI201000130A/es unknown
- 2010-07-27 DO DO2010000230A patent/DOP2010000230A/es unknown
- 2010-07-27 CR CR11596A patent/CR11596A/es not_active Application Discontinuation
- 2010-07-28 CO CO10092048A patent/CO6290672A2/es not_active Application Discontinuation
- 2010-08-23 MA MA33110A patent/MA32098B1/fr unknown
-
2012
- 2012-05-30 US US13/483,710 patent/US8530657B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8530657B2 (en) | 2013-09-10 |
CO6290672A2 (es) | 2011-06-20 |
BRPI0906567A2 (pt) | 2015-07-07 |
CN101981026A (zh) | 2011-02-23 |
CA2713367A1 (fr) | 2009-09-17 |
EP2238126B1 (fr) | 2014-11-05 |
NI201000130A (es) | 2010-12-17 |
CR11596A (es) | 2010-09-13 |
US8211892B2 (en) | 2012-07-03 |
AU2009224546A1 (en) | 2009-09-17 |
IL207195A (en) | 2013-12-31 |
EA201070895A1 (ru) | 2011-04-29 |
ECSP10010368A (es) | 2010-08-31 |
EP2238126A2 (fr) | 2010-10-13 |
TW200936136A (en) | 2009-09-01 |
AU2009224546B2 (en) | 2014-01-30 |
MX2010008290A (es) | 2010-08-18 |
PA8813701A1 (es) | 2009-09-17 |
US20120245148A1 (en) | 2012-09-27 |
US20110009391A1 (en) | 2011-01-13 |
WO2009112691A3 (fr) | 2010-01-07 |
WO2009112691A2 (fr) | 2009-09-17 |
DOP2010000230A (es) | 2010-08-31 |
AR070255A1 (es) | 2010-03-25 |
PE20091323A1 (es) | 2009-09-26 |
CL2009000173A1 (es) | 2010-02-12 |
MA32098B1 (fr) | 2011-02-01 |
IL207195A0 (en) | 2010-12-30 |
JP2011510919A (ja) | 2011-04-07 |
KR20100111308A (ko) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31616A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica | |
ECSP13012900A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
BRPI0911035B8 (pt) | ativadores de pirrolidinona glicoquinase | |
BR112013020270A2 (pt) | derivados de pirazol microbicidas | |
BR112013031463A2 (pt) | piridina-2-amidas úteis como agonistas de cb2 | |
BR112015013124A2 (pt) | novos derivados de piridina | |
BR112015012919A2 (pt) | novos derivados de piridina | |
BR112013012621A2 (pt) | heterociclos microbicidas | |
BR112015009603A2 (pt) | novos derivados de pirazina | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
BR112014010047A8 (pt) | novos derivados de pirazina | |
CR20150171A (es) | Benzamidas | |
BR112012030473A2 (pt) | pesticidas baseados em derivados pirrolidina espiroheterocíclicos | |
UY32168A (es) | Nuevas composiciones de compuestos heterociclicos nitrogenados antibacterianos con otros compuestos antibacterianos y su utilización como medicamentos | |
CU20100111A7 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares | |
BR112015032346A2 (pt) | compostos de isotiazolina para o combate de pragas de invertebrados | |
BR112015007422A2 (pt) | novos compostos farmacêuticos | |
BR112012013119A2 (pt) | derivados de 1-amino-piperidina-pirrolidina-diona espirocondensada com atividade pesticida. | |
BR112013020419A2 (pt) | microbicidas derivados de pirazol | |
BR112015006560A2 (pt) | 3-heteroaril-isoxazolina-5-carboxamidas e 3-heteroaril-isoxazolina-5-tioamidas com atividade herbicida e fungicida | |
UY31016A1 (es) | Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos | |
ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
BR112015022290A2 (pt) | derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20130225 |